Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chemical proteomics reveals the target landscape of 1,000 kinase inhibitor tool compounds

ABSTRACT: Here, we profiled the targets of 1,184 compounds from drug discovery projects in lysates of cancer cell lines using the Kinobeads approach. The resulting 500,000 compound-target interactions are available in ProteomicsDB and we exemplify how this molecular resource may be used for research. We anticipate that this molecular resource will aid drug discovery and chemical biology.

INSTRUMENT(S): Orbitrap Fusion Lumos, Q Exactive HF

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Bernhard Kuster

PROVIDER: MSV000092248 | MassIVE | Fri Jun 23 01:31:00 BST 2023

SECONDARY ACCESSION(S): PXD043230

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

Sun2019 - Predictive models of aqueous solubility of organic compounds.

Project description:Kinetic aqueous solubility (μg/mL) was experimentally determined using the same SOP in over 200 NCATS drug discovery projects. A final dataset of 11780 non-redundant molecules and their associated solubility was used to train a SVM classifier. Model Type: Predictive machine learning model. Model Relevance: Predicting the aqueous solubility of a chemical compound. Model Encoded by: Pauline (Ersilia) Metadata Submitted in BioModels by: Zainab Ashimiyu-Abdusalam Implementation of this model code by Ersilia is available here: https://github.com/ersilia-os/eos74bo

2024-04-22 | MODEL2404220003 | BioModels

Mass spectrometry based draft of the human proteome

Project description:This PXD project contains two projects published on ProteomicsDB (https://www.proteomicsDB.org) as integral part of the publication. The first project entitled 'human body map' (https://www.proteomicsdb.org/#projects/42) involves the analysis of 36 different human tissues and body fluids. The second project entitled 'Cellzome adopted' includes a collection of raw files which comprises identifications of 'missing proteins'.

2014-05-28 | PXD000865 | Pride

A CellAge epigenetic clock for expedited discovery of anti-ageing compounds in vitro

Project description:We aim to improve anti-ageing drug discovery, currently achieved through laborious and lengthy longevity analysis. Recent studies demonstrated that the most accurate molecular method to measure human age is based on CpG methylation profiles, as exemplified by several epigenetics clocks that can accurately predict an individual’s age. Here, we developed CellAge, a new epigenetic clock that measures subtle ageing changes in primary human cells in vitro. As such it provides a unique tool to measure effects of relatively short pharmacological treatments on ageing. We validated our CellAge clock against known longevity drugs such as rapamycin and trametinib. Moreover, we uncovered novel anti-ageing drugs, torin2 and Dactolisib (BEZ-235), demonstrating the value of our approach as a screening and discovery platform for anti-ageing strategies. CellAge outperforms other epigenetic clocks in measuring subtle ageing changes in primary human cells in culture. The tested drug treatments reduced senescence and other ageing markers, further consolidating our approach as a screening platform. Finally, we showed that the novel anti-ageing drugs we uncovered in vitro, indeed increased longevity in vivo. Our method expands the scope of CpG methylation profiling from measuring human chronological and biological age from human samples in years, to accurately and rapidly detecting anti-ageing potential of drugs using human cells in vitro, providing a novel accelerated discovery platform to test sought after geroprotectors.

2021-10-01 | E-MTAB-8327 | biostudies-arrayexpress

Mycobacterium tuberculosis microarray to screen anti-tuberculosis compounds

Project description:Feature reduction of microarray data from mycobacteria treated with a variety of various clinical and investigational drugs We are using feature reduction to demonstrate that subsets of biomarker genes representative of the whole genome are sufficient for MOA classification and deconvolution in a medium-throughput microfluidic format ultimately leading to a cost effective and rapid tool for routine antibacterial drug-discovery programs.

2013-04-24 | E-GEOD-46212 | biostudies-arrayexpress

ProteomeTools - Building ProteomeTools based on a complete synthetic human proteome

Project description:The ProteomeTools project aims to derive molecular and digital tools from the human proteome to facilitate biomedical and life science research. Here, we describe the generation and multimodal LC-MS/MS analysis of >350,000 synthetic tryptic peptides representing nearly all canonical human gene products. This resource will be extended to 1.4 million peptides within two years and all data will be made available to the public in ProteomicsDB.

2017-02-09 | PXD004732 | Pride

ProteomeTools – Part II - Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning

Project description:"The ProteomeTools project aims to derive molecular and digital tools from the human proteome to facilitate biomedical and life science research. Here, we describe the second iteration of the generation and multimodal LC-MS/MS analysis of >220,000 synthetic tryptic peptides representing nearly all canonical human gene products. This resource will be extended to 1.4 million peptides and all data will be made available to the public in ProteomicsDB."

2019-05-21 | PXD010595 | Pride

RA-MAP: mapping the molecular immunological landscape in early rheumatoid arthritis with vaccine controls

Project description:<p>Rheumatoid arthritis (RA) is a chronic inflammatory disorder with poorly defined aetiology characterised by synovial inflammation with variable disease severity and drug responsiveness. To investigate the peripheral blood immune cell landscape of RA, we performed comprehensive clinical and molecular profiling of 267 RA patients and 52 healthy vaccine recipients for up to 18 months to establish a high quality sample biobank including plasma, serum, peripheral blood cells, urine, genomic DNA, RNA from whole blood, lymphocyte and monocyte subsets. We have performed extensive multi-omic immune phenotyping, including genomic, metabolomic, proteomic, transcriptomic and autoantibody profiling. We anticipate that these detailed clinical and molecular data will serve as a fundamental resource offering insights into immune-mediated disease pathogenesis, progression and therapeutic response, ultimately contributing to the development and application of targeted therapies for RA.</p>

2021-06-16 | MTBLS1497 | MetaboLights

Homo sapiens

Project description:Molecular phenotyping empowers drug discovery: a proof-of-concept study

| PRJNA354350 | ENA

RA-MAP: mapping molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients [Healthy Hepatitis B Vaccine Recipients]

Project description:Rheumatoid arthritis (RA) is a chronic inflammatory disorder with poorly defined aetiology characterised by synovial inflammation with variable disease severity and drug responsiveness. To investigate the peripheral blood immune cell landscape of RA, we performed comprehensive clinical and molecular profiling of 267 RA patients and 52 vaccine recipient controls for up to 18 months to establish a high quality sample biobank including plasma, serum, peripheral blood cells, urine, genomic DNA, RNA from whole blood, lymphocyte and monocyte subsets. We have performed extensive multi-omic immune phenotyping, including genomic, metabolomic, proteomic, transcriptomic and autoantibody profiling. We anticipate that these detailed clinical and molecular data will serve as a fundamental resource offering insights into disease pathogenesis, progression and therapeutic response, ultimately contributing to the development and application of targeted therapies for RA.

2021-05-12 | GSE97475 | GEO

RA-MAP: mapping the molecular immunological landscape in early rheumatoid arthritis with vaccine controls [6 month RA, Whole Blood, PBMC, CD4, CD8, CD14]

2021-05-12 | GSE97948 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data